HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
Low Prevalence of Neurocognitive Impairment in Early Diagnosed and Managed HIV-Infected Persons
Neurol 80:371-379, Crum-Cianflone, N.,et al, 2013
Intracranial Mass Lesions in AIDS:Using Decision Analysis to Determine the Effectiveness of Stereotactic Brain Biopsy
Neurol 46:1010-1015, Holloway,R.G.,et al, 1996
Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994
Primary Central Nervous System Lymphoma
Ann Int Med 119:1093-1104, Fine,H.A.&Mayer,R.J., 1993
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Ann Neurol 94:146-159, Giraldo,G.S.P.,et al, 2023
Brain Tumors in Children
NEJM 386:1922-1931, Cohen, A.R., 2022
The COVID-19 Pandemic and the Ethical Duties of the Neurologist
Neurol 95:167-172, Rubin, M.A.,et al, 2020
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Postherpetic Neuralgia
NEJM 371:1526-1533, Johnson, R.W.,et al, 2014
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
Quality of Life in Patients with Charcot-Marie-Tooth Disease
Neurol 65:922-924, Vinci,P.,et al, 2005
Recent Developments in Bell's Palsy
BMJ 329:553-557, Holland,N.J. & Weiner,G.M., 2004
Disability and Quality of Life in Charcot-Marie-Tooth Disease Type 1
JNNP 70:548-550, Pfeiffer,G.,et al, 2001
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Impact of Interferon Beta-1A On Neurologic Disability in Relapsing Multiple Sclerosis
Neurol 49:358-363, Rudick,R.A.,et al, 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Long-Term Tacrine (Cognex) Treatment:Effects on Nursing Home Placement and Mortality
Neurol 47:166-177, Knopman,D.,et al, 1996
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Seizure Disorder
Ciba Clin Symposia 46:4-34, Devinsky,O., 1994
Recombinant Human Erythropoietin and Renal Anemia:Molecular Biology, Clinical Efficacy, and Nervous System Effects
Ann Int Med 114:402-416, Nissenson,A.R.,et al, 1991